North American Pharmaceutical — Total revenues
McKesson North American Pharmaceutical — Total revenues decreased by 16.6% to $84.16B in Q4 2026 compared to the prior quarter. Year-over-year, this metric declined by 20.7%, from $106.16B to $84.16B. Over 2 years (FY 2021 to FY 2023), North American Pharmaceutical — Total revenues shows relatively stable performance with a 3.8% CAGR. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
How to read this metric
Higher revenue indicates strong market demand, successful contract wins, or favorable pricing trends in the pharmaceutical supply chain.
Detailed definition
This metric represents the total gross sales generated by the North American Pharmaceutical segment from the distributio...
Peer comparison
The primary benchmark for scale among pharmaceutical wholesalers, directly comparable to revenue segments at Cencora and Cardinal Health.
mck_segment_north_american_pharmaceutical_total_revenuesHistorical Data
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q3 '25 | Q4 '25 | Q4 '25 | Q1 '26 | Q1 '26 | Q2 '26 | Q2 '26 | Q3 '26 | Q3 '26 | Q4 '26 | Q4 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $62.67B | $66.58B | $68.61B | $56.17B | $67.15B | $70.16B | $70.49B | $44.12B | $74.48B | $77.22B | $80.9B | $40.72B | $79.28B | $93.65B | $80.02B | $95.29B | $81.2B | $51.92B | $97.83B | $103.15B | $86.48B | $106.16B | $88.32B | $100.86B | $84.16B | $100.86B | $84.16B | $100.86B | $84.16B | $100.86B | $84.16B |
| QoQ Change | — | +6.2% | +3.1% | -18.1% | +19.6% | +4.5% | +0.5% | -37.4% | +68.8% | +3.7% | +4.8% | -49.7% | +94.7% | +18.1% | -14.6% | +19.1% | -14.8% | -36.1% | +88.4% | +5.4% | -16.2% | +22.8% | -16.8% | +14.2% | -16.6% | +19.8% | -16.6% | +19.8% | -16.6% | +19.8% | -16.6% |
| YoY Change | — | — | — | — | +7.1% | +5.4% | +2.7% | -21.5% | +10.9% | +10.1% | +14.8% | -7.7% | +6.4% | +21.3% | +3.6% | +17.8% | +0.4% | +27.5% | +23.4% | +10.1% | -7.7% | +11.4% | -7.3% | +94.3% | +62.1% | +3.1% | -14.0% | -2.2% | -18.4% | -5.0% | -20.7% |
Similar Metrics at Other Companies
Frequently Asked Questions
- What is McKesson's north american pharmaceutical — total revenues?
- McKesson (MCK) reported north american pharmaceutical — total revenues of $84.16B in Q4 2026.
- How has McKesson's north american pharmaceutical — total revenues changed year-over-year?
- McKesson's north american pharmaceutical — total revenues decreased by 20.7% year-over-year, from $106.16B to $84.16B.
- What is the long-term trend for McKesson's north american pharmaceutical — total revenues?
- Over 2 years (2021 to 2023), McKesson's north american pharmaceutical — total revenues has grown at a 3.8% compound annual growth rate (CAGR), from $257.01B to $276.71B.
- What does north american pharmaceutical — total revenues mean?
- The total sales revenue generated by the North American Pharmaceutical segment.